Global Blood Plasma Derivatives Market Size, Share, Forecast Report, 2020-2027
The global blood plasma derivatives market is expected to register ~10.1% CAGR during the forecast period of 2019 to 2025, with a market value of USD 33,590 million in 2018.
Blood plasma derivatives are concentrates of specific plasma proteins prepared from pools (many donor units) of plasma. Plasma derivatives are obtained through a process known as fractionation.
The global blood plasma derivatives market is driven by factors such as rising incidences of infectious diseases and growing demand for plasma derivatives to treat life-threatening disorders, including hemophilia.
Additionally, the rising awareness about the use of blood plasma derivatives in HIV and the increasing adoption of blood plasma derivatives products for treatments is anticipated to fuel the market growth.
For instance, according to the Centre for Disease Control and Prevention, in January 2017, in the US the number of emergency department visits with parasitic and infectious diseases as the primary diagnosis was 3.7 million.
On the other hand, safety concerns during blood transfusion are projected to hamper the growth of the market during the assessment period.
Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to sustain their position in the market.
For instance, in August 2018, Grifols expands its plasma collection network by acquiring 24 Biotest centers in the US.
Segmentation
The global blood plasma derivatives market has been segmented based type, application, end user, and region.
The global market, based on type, has been segmented into factor VIII concentrate, factor IX concentrate, albumin, immune globulins, anti-thrombin III concentrate, fresh frozen plasma (FFP), and others.
Based on application, the global market is segmented into HIV, hemophilia A, hemophilia B, hepatitis B, hepatitis C, bleeding disorders, hypogammaglobulinemia, immunodeficiency diseases, and others.
Based on end user, the global market is segmented into hospitals & clinics, blood transfusion centers, diagnostic centers, and others.
Based on type, the immune globulins segment is expected to hold a major share in the market due to the increasing preferability to treat various infectious diseases.
Based on application, the immunodeficiency diseases segment is expected to be the fastest-growing segment during the forecast period due to the rising prevalence of immunodeficiency diseases.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The blood plasma derivatives market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European blood plasma derivatives market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The blood plasma derivatives market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The blood plasma derivatives market in the Middle East & Africa has been divided into the Middle East and Africa.
Key Players
The key players operating in the global blood plasma derivatives market are Baxter BioScience, Grifols S.A., CSL Behring, ViroPharma, Inc., Talecris Biotherapeutics, Inc., Octapharma, Fusion Healthcare, SK Plasma Co., Ltd., Biotest AG, Green Cross Corporation, and Shire Plc.
Global Blood Plasma Derivatives Market, by Type
Global Blood Plasma Derivatives Market, by Application
Global Blood Plasma Derivatives Market, by End User
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers